Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $38.9152W HIGH $147.03
Volume
846.71 K
Value Traded
35.22 M
Short % Float
14.41%
-4.69%Week
+0.32%1 Month
+28.84%3 Month
+23.45%6 Month
-76.51%5 Year
+79.01%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.93 B
EPS (TTM)
4.67
P/E Ratio
14.28
Ent. Value
1.51 B
Total Shares
28.91 M
Float Shares
27.26 M
Insiders
5.72%
Institutions
124.04%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
INSP Catalyst Timeline
Dated clinical, regulatory and corporate events for Inspire Medical Systems, Inc.
Past FDA Catalysts and PDUFA Decisions
How INSP actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D23 / 100
Pipeline Score
$0M
Pipeline Value
Not rated
Valuation Signal
1
Drugs Scored
-
rNPV / MCap
Top 88%
Small Cap(rank 579 of 658)
Percentile Rank
Inspire Medical Systems, Inc. faces pipeline headwinds (23/100), with 1 assets in development.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every INSP program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Inspire therapy | obstructive sleep apnea | 2026-06-16 | Significant reductions in hypoxic burden; Improvements in daytime sleepiness that correlate with hypoxic burden reduction, independent of AHI or arousal index changes; Meaningful hypoxic burden improvements in at least 50% of AHI non-respondersRead More | Inspire Medical Systems, Inc. Announces Presence at SLEEP 2026 and Publication of PREDICTOR StudyRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Kelly Jason POfficer (See Remarks) | Sell | -963 18,985 held | $59.55 | 08/07/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in INSP
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SOLEUS CAPITAL MANAGEMENT, L.P. | 3 % (200 %) | 86.16 M | 1.93 M | 545.1% ( 1.63 M) |
INSP Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How INSP ranks across every disease it competes in
Competitive Position is a premium feature
See how INSP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialINSP News
INSP▼ -1.1%today
Inspire Medical Systems, Inc. to Report Third Quarter 2026 Financial Results on November 2, 2026
Inspire Medical Systems, Inc. will announce its third quarter 2026 financial results on November 2, 2026. A conference call will follow at 5:00 p.m. ET to discuss these results and recent developments. Investors can access the call via the company's website, and a replay will be available afterward.
Read more →INSPInspire Medical Systems, Inc. Announces Approval of New Hypoglossal Nerve Stimulation CPT® Codes by the AMA Editorial Panel
Inspire Medical Systems has announced the approval of new CPT codes for its Inspire V system by the AMA, effective January 1, 2028. This development aims to streamline coding and reimbursement processes, potentially improving patient access to Inspire therapy. The approval received significant support from various medical societies, highlighting the growing clinical evidence for hypoglossal nerve stimulation therapies.
Read more →INSPInspire Medical Systems, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference
Inspire Medical Systems, Inc. will present at the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026. The presentation will highlight their innovative solutions for obstructive sleep apnea and will be accessible via a live webcast. A replay will be available for two weeks post-event.
Read more →INSP▲ +22.8%on this news
Inspire Medical Systems, Inc. Announces Second Quarter 2026 Financial Results, Raised 2026 Guidance, and Strategic Growth Plan
Inspire Medical Systems reported its second quarter 2026 financial results, revealing a revenue of $200.6 million, a 7.6% decrease from the previous year. The company announced a strategic growth plan, Project Horizon, aimed at generating $30 million in annualized growth investment capacity. Despite challenges in U.S. revenue and a high effective tax rate, Inspire's operating cash flow improved significantly, reflecting a focus on long-term growth.
Read more →INSPInspire Medical Systems, Inc. Announces Appointment of Seasoned Medical Device Executive Michael H. Carrel to its Board of Directors
Inspire Medical Systems has appointed Michael H. Carrel to its Board of Directors, effective July 20, 2026. Carrel, a seasoned medical device executive, brings significant experience from his previous roles, including CEO of AtriCure. His appointment comes as Inspire continues to develop its innovative therapies for obstructive sleep apnea, including the recent launch of its fifth-generation device.
Read more →INSPInspire Medical Systems, Inc. Announces Retirement of Casey M. Tansey from its Board of Directors
Inspire Medical Systems, Inc. has announced the retirement of Casey M. Tansey from its Board of Directors after over eighteen years of service, effective July 30. Tansey has been instrumental in the company's growth since its inception and was a key investor during its early financing stages. The company plans to appoint a new director to fill his position soon.
Read more →INSPCorrection: Inspire Medical Systems, Inc. to Report Second Quarter 2026 Financial Results on August 3, 2026
Inspire Medical Systems, Inc. has corrected the date for its second quarter 2026 financial results, which will now be released on August 3, 2026. The management team will host a conference call at 5:00 p.m. Eastern Time to discuss the results and recent developments. A webcast will be available for those interested in listening.
Read more →INSP▲ +5.3%on this newsshared move
Inspire Medical Systems, Inc. to Report Second Quarter 2026 Financial Results on July 6, 2026
Inspire Medical Systems, Inc. will announce its financial results for Q2 2026 on August 3, 2026. A conference call will follow at 5:00 p.m. ET to discuss these results and recent business developments. The call will be accessible via webcast, and a replay will be available afterward.
Read more →INSPInspire Medical Systems, Inc. Announces Presence at SLEEP 2026 and Publication of PREDICTOR Study
Inspire Medical Systems announced its participation in SLEEP 2026, showcasing advancements in its Inspire platform and presenting new clinical data on the effectiveness of Inspire therapy for obstructive sleep apnea (OSA). The company highlighted significant findings on hypoxic burden and cardiovascular outcomes, emphasizing the therapy's benefits over traditional CPAP. Additionally, the publication of the PREDICTOR study suggests potential for streamlined patient screening.
Read more →INSPInspire Medical Systems, Inc. to Participate in the Wells Fargo 2026 MedTech Innovation Spotlight
Inspire Medical Systems, Inc. will participate in the Wells Fargo 2026 MedTech Innovation Spotlight on June 26, 2026. The management team is scheduled to present at 10:00 a.m. ET, with a live webcast available. The presentation will be archived for two weeks on Inspire's investor website. Inspire specializes in minimally invasive solutions for obstructive sleep apnea.
Read more →INSPInspire Medical Systems, Inc. Announces First Quarter 2026 Financial Results and Updates 2026 Guidance
Inspire Medical Systems reported a 1.6% revenue growth for Q1 2026, totaling $204.6 million. Despite an operating loss of $1.1 million, the company improved its adjusted operating income and cash flow. However, ongoing challenges related to coding and reimbursement uncertainties are anticipated to affect performance throughout the year, with a revised revenue outlook for 2026 indicating a potential decline.
Read more →INSPInspire Medical Systems, Inc. to Present at the BofA Securities 2026 Healthcare Conference
Inspire Medical Systems, Inc. will present at the BofA Securities 2026 Healthcare Conference on May 13, 2026. The presentation will be available via a live webcast, with a replay accessible for two weeks afterward. Inspire specializes in minimally invasive solutions for obstructive sleep apnea, with its Inspire therapy being FDA approved.
Read more →INSPInspire Medical Systems, Inc. to Report First Quarter 2026 Financial Results on May 4, 2026
Inspire Medical Systems, Inc. will announce its financial results for the first quarter of 2026 on May 4, 2026, after market close. A conference call will follow at 5:00 p.m. ET, where management will discuss the results and recent developments. Interested parties can access the call via a webcast or register to ask questions.
Read more →INSPInspire Medical Systems, Inc. to Present at the KeyBanc Capital Markets Healthcare Forum
Inspire Medical Systems, Inc. will present at the KeyBanc Capital Markets Healthcare Forum on March 17, 2026. The presentation is scheduled for 1:30 p.m. Eastern Time and will be available via live webcast. A replay will be accessible for two weeks on Inspire's Investor website. Inspire specializes in minimally invasive solutions for obstructive sleep apnea.
Read more →INSP▼ -12.5%on this news
Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results
Inspire Medical Systems reported strong financial results for Q4 and full year 2025, highlighting the successful launch of the Inspire V system and FDA approval for 3.0T MRI compatibility. Despite a dynamic reimbursement landscape, the company remains optimistic about its growth trajectory. However, there are concerns regarding coding changes that could affect physician reimbursement rates.
Read more →INSPInspire Medical Systems, Inc. Announces Preliminary Unaudited Revenue Results for the Fourth Quarter and Full Year 2025 and Provides Initial 2026 Revenue Guidance
Inspire Medical Systems, Inc. has announced preliminary unaudited revenue results for Q4 and the full year 2025, reporting significant growth of approximately 12% and 14% year-over-year, respectively. The company has provided initial revenue guidance for 2026, anticipating a 10-11% increase. Additionally, Matt Osberg has been appointed as the new CFO, effective January 19, 2026. While the results are promising, they remain subject to audit, and current outlook does not factor in potential reimbursement increases.
Read more →INSPInspire Medical Systems, Inc. to Present at the 44th Annual J.P. Morgan Healthcare Conference
Inspire Medical Systems, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The presentation will highlight the company's innovative solutions for obstructive sleep apnea, including its FDA-approved Inspire therapy. A live webcast will be available, along with a replay for two weeks post-event.
Read more →INSP▼ -13.4%on this news
Inspire Medical Systems, Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2024 and Provides Initial 2025 Revenue Guidance
Inspire Medical Systems, Inc. announced preliminary, unaudited results for the fourth quarter and full year of 2024, reporting a revenue growth of approximately 25% for Q4 and 28% for the full year. The company has also provided initial revenue guidance for 2025, anticipating a growth of 17% to 19%. Inspire activated 72 new medical centers in the U.S. and initiated the soft launch of the Inspire V neurostimulator. Additionally, the company outlined a new organizational structure aimed at fueling continued growth and enhancing therapy adoption.
Read more →INSP▲ +6.2%on this news
Inspire Medical Systems, Inc. Announces Preliminary Results for Second Quarter of 2024 and Updates 2024 Revenue Outlook MINNEAPOLIS, MN
Inspire Medical Systems, Inc. has announced preliminary, unaudited results for the second quarter of 2024, expecting revenues of $195.9 million, a 30% increase from the previous year. The U.S. revenue alone is anticipated to be $187.8 million, signaling robust growth. The company has updated its full-year revenue outlook, now estimating between $788 million and $798 million for 2024, which is an increase from earlier projections. A complete financial report will be released on August 6, 2024.
Read more →INSP▲ +9.2%on this news
Inspire Medical Systems, Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2023 and Provides Initial 2024 Guidance
Inspire Medical Systems, Inc. reported preliminary unaudited revenue results for Q4 2023 and full year 2023, showing significant growth. The company anticipates a revenue increase of approximately 40% in Q4 compared to the previous year and a total revenue for 2023 of around $625 million. Inspire has activated 78 new centers and created 13 new sales territories in the U.S. Looking ahead, the company projects a revenue growth of 24% to 26% for 2024. These positive results reflect the successful execution of their business strategy and operational leverage.
Read more →About Inspire Medical Systems, Inc.
Headquarters5500 WAYZATA BLVD, GOLDEN VALLEY, MN, 55416
BIOPHARMAWATCH ELITE PLUS
Trade the next INSP catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime